Annual Report 2019
It is important to note too, that JanssenPharmaceuticals, a division of Johnson and Johnson, have now demonstrated thereis a class of drug (gliflozins) able to treat diabetic kidney disease oncediagnosed. It is this drug which we are testing in collaboration with ourstrategic partner Janssen Research and Development. The results from thisexciting collaborative study are due late this calendar year. If a successfulcorrelation can be established, PromarkerD may become a ComplementaryDiagnostic (CDx) for such drugs, potentially being utilised every time aprescription is issued.
Ann: PromarkerD latest results published in peer reviewed journal, page-22
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
-0.015(4.92%) |
Mkt cap ! $47.42M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 31.0¢ | 28.5¢ | $191.2K | 643.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 53694 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 51000 | 2 |
View Market Depth
| Last trade - 15.36pm 26/06/2025 (20 minute delay) ? |
| PIQ (ASX) Chart |